|
1
|
Bordon Y: Immunotherapy: Checkpoint
parley. Nat Rev Cancer. 15:32015. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: KEYNOTE-024 Investigators: Pembrolizumab versus
chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl
J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weber JS, DAngelo SP, Minor D, Hodi FS,
Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD,
et al: Nivolumab versus chemotherapy in patients with advanced
melanoma who progressed after anti-CTLA-4 treatment (CheckMate
037): A randomised, controlled, open-label, phase 3 trial. Lancet
Oncol. 16:375–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iwai Y, Ishida M, Tanaka Y, Okazaki T,
Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the
escape from host immune system and tumor immunotherapy by PD-L1
blockade. Proc Natl Acad Sci USA. 99:12293–12297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang Y, Pang Z, Ding N, Dong W, Ma W, Li
Y, Du J and Liu Q: The efficacy and potential predictive factors of
PD-1/PD-L1 blockades in epithelial carcinoma patients: A systematic
review and meta analysis. Oncotarget. 7:74350–74361.
2016.PubMed/NCBI
|
|
7
|
Shintani Y, Okimura A, Sato K, Nakagiri T,
Kadota Y, Inoue M, Sawabata N, Minami M, Ikeda N, Kawahara K, et
al: Epithelial to mesenchymal transition is a determinant of
sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann
Thorac Surg. 92:1794–1804; discussion 1804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shintani Y, Abulaiti A, Kimura T, Funaki
S, Nakagiri T, Inoue M, Sawabata N, Minami M, Morii E and Okumura
M: Pulmonary fibroblasts induce epithelial mesenchymal transition
and some characteristics of stem cells in non-small cell lung
cancer. Ann Thorac Surg. 96:425–433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim
TM, Lee SH, Min HS, Kim YT, Kim DW, et al: Clinicopathologic
analysis of programmed cell death-1 and programmed cell
death-ligand 1 and 2 expressions in pulmonary adenocarcinoma:
Comparison with histology and driver oncogenic alteration status.
Mod Pathol. 28:1154–1166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shintani Y, Maeda M, Chaika N, Johnson KR
and Wheelock MJ: Collagen I promotes epithelial-to-mesenchymal
transition in lung cancer cells via transforming growth factor-beta
signaling. Am J Respir Cell Mol Biol. 38:95–104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McCarty KS Jr, Szabo E, Flowers JL, Cox
EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman
WT, et al: Use of a monoclonal anti-estrogen receptor antibody in
the immunohistochemical evaluation of human tumors. Cancer Res. 46
(Suppl):4244s–4248s. 1986.PubMed/NCBI
|
|
12
|
Shintani Y, Fujiwara A, Kimura T, Kawamura
T, Funaki S, Minami M and Okumura M: IL-6 decreted from
cancer-associated fibroblasts mediates chemoresistance in NSCLC by
increasing epithelial-mesenchymal transition signaling. J Thorac
Oncol. 11:1482–1492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Abulaiti A, Shintani Y, Funaki S, Nakagiri
T, Inoue M, Sawabata N, Minami M and Okumura M: Interaction between
non-small-cell lung cancer cells and fibroblasts via enhancement of
TGF-β signaling by IL-6. Lung Cancer. 82:204–213. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schats KA, Van Vré EA, De Schepper S,
Boeckx C, Schrijvers DM, Waelput W, Fransen E, Vanden Bempt I,
Neyns B, De Meester I, et al: Validated programmed cell death
ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal
similar immune cell staining patterns in melanoma when using the
same sensitive detection system. Histopathology. 70:253–263. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Smith J, Robida MD, Acosta K, Vennapusa B,
Mistry A, Martin G, Yates A and Hnatyszyn HJ: Quantitative and
qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
Diagn Pathol. 18:442016. View Article : Google Scholar
|
|
17
|
Thomson S, Petti F, Sujka-Kwok I, Mercado
P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM and Haley
JD: A systems view of epithelial-mesenchymal transition signaling
states. Clin Exp Metastasis. 28:137–155. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shimoji M, Shimizu S, Sato K, Suda K,
Kobayashi Y, Tomizawa K, Takemoto T and Mitsudomi T: Clinical and
pathologic features of lung cancer expressing programmed cell death
ligand 1 (PD-L1). Lung Cancer. 98:69–75. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim
JH, Jeon YK, Lee JS, Kwon SK, Hah JH, et al: PD-L1 expression is
associated with epithelial-mesenchymal transition in head and neck
squamous cell carcinoma. Oncotarget. 7:15901–15914. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang P, Su DM, Liang M and Fu J:
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1)
surface expression in breast cancer cells and promote
PD-L1-mediated T cell apoptosis. Mol Immunol. 45:1470–1476. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hecht M, Büttner-Herold M,
Erlenbach-Wünsch K, Haderlein M, Croner R, Grützmann R, Hartmann A,
Fietkau R and Distel LV: PD-L1 is upregulated by radiochemotherapy
in rectal adenocarcinoma patients and associated with a favourable
prognosis. Eur J Cancer. 65:52–60. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Noman MZ, Desantis G, Janji B, Hasmim M,
Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct
target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G,
McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M,
Stewart R, et al: Acquired resistance to fractionated radiotherapy
can be overcome by concurrent PD-L1 blockade. Cancer Res.
74:5458–5468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deng L, Liang H, Burnette B, Beckett M,
Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1
treatment synergistically promote antitumor immunity in mice. J
Clin Invest. 124:687–695. 2014. View
Article : Google Scholar : PubMed/NCBI
|
